Evoxac
Evoxac Uses, Dosage, Side Effects, Food Interaction and all others data.
Evoxac is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Evoxac is a cholinergic agonist which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointestinal and urinary tracts.
| Trade Name | Evoxac |
| Availability | Prescription only |
| Generic | Cevimeline |
| Cevimeline Other Names | Cevimelina, Cévimèline, Cevimeline, Cevimelinum |
| Related Drugs | Evoxac |
| Weight | 30mg, |
| Type | Oral capsule |
| Formula | C10H17NOS |
| Weight | Average: 199.313 Monoisotopic: 199.103084861 |
| Protein binding | < 20% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Evoxac is a muscarinic agonist with parasympathomimetic activities that is used for the symptomatic treatment of dry mouth in patients with Sjögren's Syndrome.
For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Evoxac is also used to associated treatment for these conditions: Dry Mouth
How Evoxac works
Muscarinic agonists such as cevimeline bind and activate the muscarinic M1 and M3 receptors. The M1 receptors are common in secretory glands (exocrine glands such as salivary and sweat glands), and their activation results in an increase in secretion from the secretory glands. The M3 receptors are found on smooth muscles and in many glands which help to stimulate secretion in salivary glands, and their activation generally results in smooth muscle contraction and increased glandular secretions. Therefore, as saliva excretion is increased, the symptoms of dry mouth are relieved.
Food Interaction
No interactions found.Evoxac Drug Interaction
Moderate: duloxetine, duloxetine, hydroxychloroquine, hydroxychloroquineUnknown: omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, cyclosporine ophthalmic, cyclosporine ophthalmic, levothyroxine, levothyroxine, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, ergocalciferol, ergocalciferol, cholecalciferol, cholecalciferol, cetirizine, cetirizine
Evoxac Disease Interaction
Major: cardiovascular disease, glaucoma, pulmonary diseaseModerate: cholelithiasis, nephrolithiasis
Volume of Distribution
- 6 L/kg
Elimination Route
Rapidly absorbed with peak concentration after 1.5 to 2 hours
Half Life
5 ± 1 hours
Elimination Route
After 24 hours, 84% of a 30 mg dose of cevimeline was excreted in urine.
Innovators Monograph
You find simplified version here Evoxac
